Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Dusseldorf - Delayed Quote EUR

Jazz Pharmaceuticals PLC (J7Z.DU)

Compare
140.00
+7.00
+(5.26%)
At close: February 27 at 4:00:10 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for J7Z.DU

Recent News: J7Z.DU

View More
Despite the downward trend in earnings at Jazz Pharmaceuticals (NASDAQ:JAZZ) the stock advances 3.2%, bringing five-year gains to 21%

Despite the downward trend in earnings at Jazz Pharmaceuticals (NASDAQ:JAZZ) the stock advances 3.2%, bringing five-year gains to 21%
Simply Wall St. yesterday
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
PR Newswire 2 days ago
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
PR Newswire 7 days ago
Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025
PR Newswire 16 days ago
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire 2 months ago
Jazz Pharmaceuticals Announces CEO Succession Plan

Jazz Pharmaceuticals Announces CEO Succession Plan
PR Newswire 2 months ago
Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?

Is Now The Time To Put Jazz Pharmaceuticals (NASDAQ:JAZZ) On Your Watchlist?
Simply Wall St. 2 months ago
Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch

Jazz upgraded to Overweight at Morgan Stanley after Ziihera launch
TipRanks 2 months ago
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
PR Newswire 2 months ago
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
PR Newswire 2 months ago
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
PR Newswire 2 months ago
View More

Related Tickers

MAGLE.ST Magle Chemoswed Holding AB (publ)
31.00
-4.32%
 
NV3P.F NanoViricides, Inc.
1.1800
+4.42%
 
C4X.F Valerio Therapeutics Société anonyme
0.0511
-0.39%
 
HQ1.MU Oruka Therapeutics Inc. R
10.20
-0.97%
 
RGO.DU Regeneron Pharmaceuticals Inc
670.80
-1.93%
 
MOC.WA Molecure S.A.
8.99
-0.11%
 
PH4.F CStone Pharmaceuticals
0.4500
+4.17%
 
BSSP Baseline Productions, Inc.
0.0001
0.00%
 
ARDX.MX Ardelyx, Inc.
105.50
0.00%
 
AREC.L Arecor Therapeutics plc
50.00
-2.91%